Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06442462
Status:
RECRUITING
Last Update Posted:
2024-07-09
First Post:
2024-05-29
Brief Title:
Study of SPG302 in Adults With Schizophrenia
Sponsor:
Spinogenix
Organization:
Spinogenix
Study Overview
Official Title:
A Randomized Placebo-controlled Double-blind Phase 2 Study to Assess the Efficacy Safety Tolerability and Pharmacodynamics of SPG302 in Adult Participants Diagnosed With Schizophrenia
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This Phase 2 study described herein will evaluate the safety efficacy tolerability and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia
Detailed Description:
This Phase 2 study will evaluate the safety efficacy tolerability and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia This is a randomized placebo-controlled study of SPG302 administered once daily for six weeks
This study will entail five visits to the study site for screening study procedures and receipt of investigational medication for use at home
This study will entail five visits to the study site for screening study procedures and receipt of investigational medication for use at home
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None